SIRION Biotech Customised Viral Vectors for Cell Modelling, Gene Therapy, and Vaccination Research and Development

Viral vector systems to improve transduction

SIRION Biotech offers custom engineering of viral vectors to improve transduction and performance of in-vitro cell modelling, in-vivo gene modification and therapeutic research and development (R&D).

The company’s virus-based technologies are used worldwide in academia and industry. SIRION’s strong focus on transduction technologies enables it to offer customisation services for all three major virus types, lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).

Viral vector engineering and manufacture

SIRION engineers and manufactures replication-deficient LV, AAV and AV vectors. The platform offers many add-on options such as inducible expression systems, tissue-specific promoters and specialised transduction boosters for tight expression control.

Custom adeno-associated virus service

SIRION can manufacture a range of AAV serotypes and can engineer these with tissue-specific promotors to increase expression precision of nearly any gene of interest.

Fast protein liquid chromatography (FPLC) grade AAV manufacture techniques provide high-purity products for R&D in less than eight weeks. The sophisticated platform allows the integration of desired expression constructs within the vector’s cloning capacity. Batch sizes range from 5×1011 genetic copies (GC) for small explorative experiments all the way to 5×1014 GC to satisfy complete experimental cohorts.

Additional in-house features of the SIRION AAV technology platform include capsid modifications to target cell-specific transduction. All projects are personally planned with highly trained project managers to ensure resulting vector designs and function fit the client’s intended application.

Custom lentivirus service

SIRION BIOTECH`s custom LV vector service enables the manufacture of constitutive and inducible gene vectors in less than four weeks.

SIRION’s multicistronic vector designs enable customers to create highly homogeneous, stable cell pools, and avoid time-consuming clone selection after transduction.

With the all-in-one inducible vector system, SIRION enables working with difficult cytotoxic genes and knockdown strategies. The manufacture of scales up to 1×109 TU is possible.

Custom adenovirus service

SIRION`s patented BAC technology enables AV construction in less than five weeks.

The system complies with standard safety criteria by using replication-deficient E1/E3 deleted serotype Ad5 as base vector. Desired genes or knockdown expression construct is possible, within a 7.5kb limit.

Transduction enhancers for difficult cell types

SIRION’s in-house developed transduction boosters enable working with difficult-to-transduce cell types such as hematopoietic cells.

The LentiBOOST™ reagent is currently used in several clinical trials to improve genetic modification of hematopoietic stem cells or T-cells for gene-therapy and chimeric antigen receptor T-cell (CAR-T) cell projects.

Developing novel AAV for gene therapy – NextGen AAV

AAVs are heavily utilised in modern gene therapy trials. While standard AAV applications are suitable for pre-clinical target validation and proof-of-principle experiments, they often fall short during the big step into clinical application.

SIRION´s AAV optimisation platform enables you to address AAV limitations before you take that crucial step. All elements of your AAV strategy are considered and optimised with your project’s specific goals in mind.

About SIRION Biotech

SIRION Biotech is a globally active technology provider with a strong customer base in the fields of cancer research, neurosciences, regenerative medicines, gene therapy, CAR T-cell development and R&D of new vaccination methods.

The company was founded in 2007 at the IZB in Martinsried near Munich, Germany. It was designed to shift the paradigm of viral vector technologies and supplies.

Today, the company has more than 500 ongoing projects. SIRION Biotech understands its customers’ technical challenges and offers specialised individual solutions for projects of all sizes.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Key Candidate hAd19a/64 Outperforms Gold-Standard hAd5 as a Vaccine Vehicle

A recent collaboration between University of Copenhagen's associate professor Peter Johannes Holst, his research group, colleagues at Bogor Agricultural University, and Munich-based viral vector company SIRION Biotech demonstrated that key candidate hAd19a/64 can outperform counterpart and gold-standard hAd5 as a vaccine vehicle.

Product and Services
White Papers

Master Gene Copy Numbers in Hematopoietic Stem Cells

Transduction enhancers help increase the chances of success for blood-cell targeted gene therapies.

Address
SIRION BIOTECH GmbH

Am Klopferspitz 19

82152 Martinsried

Germany

+49 897 009 61999 +1 857 284 1844 (US) www.sirion-biotech.com

SIRION Biotech Images

Video

Related Projects



Press Release

11 September 2018

A recent collaboration between University of Copenhagen's associate professor Peter Johannes Holst, his research group, colleagues at Bogor Agricultural University, and Munich-based viral vector company SIRION Biotech demonstrated that key candidate hAd19a/64 can outperform counterpart and gold-standard hAd5 as a vaccine vehicle.

Read more
19 July 2018

The viral vector specialist SIRION Biotech has announced the signing of a preferred partnership agreement with Heidelberg University Hospital and adeno-associated virus (AAV) pioneer Professor Dirk Grimm.

Read more
21 September 2017

Sirion Biotech has announced it will be attending the ESGCT XXV Anniversary Congress, in collaboration with the German Society for Gene Therapy DG-GT.

Read more
27 July 2017

Novartis has announced its CAR-T cell therapy CTL019 has been recommended by the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC).

Read more
4 July 2017

Gene delivery by viral vectors has taken centre stage in the development of gene therapies and immuno-oncologies. It has revolutionised the precision that complex cell models can be realised.

Read more
30 May 2017

Off-the shelf virus vectors are naturally limited to answer only a basic set of questions. This can lead experimenters to compromise their work.

Read more
27 April 2017

Known as transduction, the application of virus particles to deliver gene constructs to a cell is one of the best and most efficient ways to genetically modify mammalian or human tissue.

Read more
15 December 2016

Sirion Biotech has announced that the Ad19a/64 vectors, considered by insiders as a promising vaccination and immune oncolgy tool, can act as a powerful prime reagent in a two-step prime boost vaccination approach.

Read more

Regional Offices

SIRION BIOTECH GmbH

Am Klopferspitz 19

82152 Martinsried

Germany

+49 897 009 61999 +1 857 284 1844 (US) www.sirion-biotech.com

Contact company

I have read and accept the terms and conditions and privacy policys.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.